"FDA Grants Breakthrough Therapy Designation for LSD-Based Anxiety Medication"
TL;DR Summary
The FDA has granted breakthrough therapy status to an LSD formulation, MM120, for treating generalized anxiety disorder, with promising results from a Phase 2 trial showing significant symptom improvement and remission in patients. This designation is expected to bring in a substantial investment for further development, and MindMed plans to begin Phase 3 trials later this year.
- FDA: LSD Is Now a Breakthrough Therapy Newser
- LSD-Based Med for Anxiety Receives FDA Breakthrough Status Medscape
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder Business Wire
- MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag Yahoo Finance
- Single LSD dose provides lasting anxiety relief: Research The Hill
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
80%
291 → 57 words
Want the full story? Read the original article
Read on Newser